Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival

2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Dieci, 2020, Should triple-positive breast cancer be recognized as a distinct subtype?, Expert Rev Anticancer Ther, 20, 1011, 10.1080/14737140.2020.1829484 Untch, 2008, Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial, Ann Oncol, 19, 1090, 10.1093/annonc/mdn005 Anderson, 2002, Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database, Breast Cancer Res Treat, 76, 27, 10.1023/A:1020299707510 Cui, 2005, Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy, J Clin Oncol, 23, 7721, 10.1200/JCO.2005.09.004 Rakha, 2007, Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype, J Clin Oncol, 25, 4772, 10.1200/JCO.2007.12.2747 Colleoni, 2008, Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy, Ann Oncol, 19, 465, 10.1093/annonc/mdm509 Colleoni, 2009, Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy, Breast Cancer Res Treat, 116, 359, 10.1007/s10549-008-0223-y Bao, 2011, Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study, Am J Epidemiol, 174, 661, 10.1093/aje/kwr145 Li, 2020, Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone receptor-positive breast cancer, JAMA Netw Open, 3, e1918160, 10.1001/jamanetworkopen.2019.18160 Delvallee, 2021, Negative estrogen receptors and positive progesterone receptors breast cancers, J Gynecol Obstet Hum Reprod, 50, 101928, 10.1016/j.jogoh.2020.101928 Ahmed, 2017, Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group, J Clin Pathol, 70, 320, 10.1136/jclinpath-2016-203847 Maleki, 2012, ER-negative /PR-positive breast carcinomas or technical artifacts in immunohistochemistry?, Arch Iran Med, 15, 366 Itoh, 2014, Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers, Breast Cancer Res Treat, 143, 403, 10.1007/s10549-013-2763-z Foley, 2018, Re-appraisal of estrogen receptor negative/progesterone receptor positive (ER-/PR+) breast cancer phenotype: true subtype or technical artefact?, Pathol Oncol Res, 24, 881, 10.1007/s12253-017-0304-5 Braun, 2013, Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss, Mod Pathol, 26, 1161, 10.1038/modpathol.2013.60 Purdie, 2014, Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study, Br J Cancer, 110, 565, 10.1038/bjc.2013.756 Zhao, 2019, Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer, Theranostics, 9, 4935, 10.7150/thno.35730 Alqaisi, 2014, Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research, Breast Cancer Res Treat, 148, 437, 10.1007/s10549-014-3145-x Huo, 2017, Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas, JAMA Oncol, 3, 1654, 10.1001/jamaoncol.2017.0595 Anderson, 2001, Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database, J Clin Oncol, 19, 18, 10.1200/JCO.2001.19.1.18 Prat, 2015, Clinical implications of the intrinsic molecular subtypes of breast cancer, Breast, 24, S26, 10.1016/j.breast.2015.07.008 Bae, 2015, Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer, BMC Cancer, 15, 138, 10.1186/s12885-015-1121-4 McGuire, 2017, Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab, Breast Cancer Res Treat, 164, 221, 10.1007/s10549-017-4225-5 Parise, 2014, Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers, J Cancer Epidemiol, 2014, 469251 Chen, 2017, Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis, Sci Rep, 7, 9254, 10.1038/s41598-017-10166-8 Chang, 2019, Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database, Breast Cancer Res Treat, 173, 209, 10.1007/s10549-018-4968-7 Ren, 2019, Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics, Breast Cancer Res Treat, 173, 225, 10.1007/s10549-018-4956-y Xiao, 2018, Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study, Cancer Manag Res, 10, 5329, 10.2147/CMAR.S176763 Arpino, 2005, Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance, J Natl Cancer Inst, 97, 1254, 10.1093/jnci/dji249 Marchio, 2008, The genomic profile of HER2-amplified breast cancers: the influence of ER status, J Pathol, 216, 399, 10.1002/path.2423 Vici, 2015, Triple positive breast cancer: a distinct subtype?, Cancer Treat Rev, 41, 69, 10.1016/j.ctrv.2014.12.005 Viale, 2018, Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial, Breast Cancer Res Treat, 167, 123, 10.1007/s10549-017-4509-9 Luo, 2019, Prognostic nomogram for patients with non-metastatic HER2 positive breast cancer in a prospective cohort, Int J Biol Markers, 34, 41, 10.1177/1724600818824786